Compounding pharmacies create these formulations under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act
As clinical data showing dramatic weight loss results with semaglutide and tirzepatide reached mainstream awareness, demand for these medications surged far beyond what manufacturers could supply
10.1016/j.taap.2004.12.016
Labs are a tool for monitoring, not a requirement for treatment
According to Visiongain analysis, the global Anti-Obesity Drugs Market is expected to surpass US$22.5 billion in 2026 and reach US$199.9 billion by 2036, representing a compound annual growth rate of 24.2 per cent
Anand U, Yiangou Y, Akbar A, Quick T, MacQuillan A, Fox M, Sinisi M, Korchev YE, Jones B, Bloom SR, Anand P (2018) Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons